Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience.

dc.contributor.authorMozas, Pablo
dc.contributor.authorNadeu Prat, Ferran
dc.contributor.authorRivas Delgado, Alfredo
dc.contributor.authorRivero, Andrea
dc.contributor.authorGarrote i Ordeig, Marta
dc.contributor.authorBalagué Ponz, Olga
dc.contributor.authorGonzález Farré, Blanca
dc.contributor.authorVeloza, Luis
dc.contributor.authorBaumann, Tycho
dc.contributor.authorGiné Soca, Eva
dc.contributor.authorDelgado, Julio (Delgado González)
dc.contributor.authorVillamor i Casas, Neus
dc.contributor.authorCampo Güerri, Elias
dc.contributor.authorMagnano, Laura
dc.contributor.authorLópez Guillermo, Armando
dc.date.accessioned2021-07-06T15:01:37Z
dc.date.available2021-07-06T15:01:37Z
dc.date.issued2020-03-05
dc.date.updated2021-07-06T15:01:37Z
dc.description.abstractAlthough the introduction of immunotherapy has improved outcomes for follicular lymphoma (FL) patients, histological transformation (HT) and early relapse still confer a poor prognosis. We sought to describe the patterns of change in treatment, response, and outcome of FL patients at our institution over the last four decades. Seven hundred and twenty-seven patients (389 F/338 M; median age, 57 years) consecutively diagnosed with grade 1-3a FL between 1980 and 2017, categorized into four decades according to the time of diagnosis, constituted the study population. Clinical characteristics, treatment, response, absolute and relative survival, HT, second malignancies (SM), and causes of death were assessed. Median OS for the entire cohort was 17.6 years. From decade 1 to 4, there was an increase in the complete response rate (48 to 70%), progression-free survival (40 to 56% at 5 years), OS (77 to 86% at 5 years), and relative survival ratio (0.83 to 0.94 at 5 years), with no significant differences in the risk of HT or SM. Lymphoma remained the most common cause of death in all four decades. These findings illustrate the overall improvement in outcome for FL patients, but support the need for further research into risk stratification and management.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec701537
dc.identifier.issn2044-5385
dc.identifier.pmid32139690
dc.identifier.urihttps://hdl.handle.net/2445/178866
dc.language.isoeng
dc.publisherSpringer Nature
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41408-020-0299-0
dc.relation.ispartofBlood Cancer Journal, 2020, vol. 10, num. 31
dc.relation.urihttps://doi.org/10.1038/s41408-020-0299-0
dc.rightscc-by (c) Mozas, Pablo et al., 2020
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Fonaments Clínics)
dc.subject.classificationImmunoteràpia
dc.subject.classificationLimfomes
dc.subject.otherImmunotheraphy
dc.subject.otherLymphomas
dc.titlePatterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience.
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
701537.pdf
Mida:
822.53 KB
Format:
Adobe Portable Document Format